Ascentage Pharma Group International's (NASDAQ:AAPG - Get Free Report) lock-up period will end on Wednesday, July 23rd. Ascentage Pharma Group International had issued 7,325,000 shares in its IPO on January 24th. The total size of the offering was $126,356,250 based on an initial share price of $17.25. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.
Analyst Ratings Changes
Separately, JPMorgan Chase & Co. initiated coverage on shares of Ascentage Pharma Group International in a research note on Thursday, March 27th. They issued an "overweight" rating on the stock.
View Our Latest Research Report on Ascentage Pharma Group International
Ascentage Pharma Group International Trading Up 1.9%
NASDAQ:AAPG traded up $0.77 during midday trading on Friday, reaching $40.39. 7,108 shares of the stock traded hands, compared to its average volume of 11,795. The firm has a 50-day moving average price of $32.56. Ascentage Pharma Group International has a 12-month low of $16.50 and a 12-month high of $43.58. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 3.24.
Institutional Trading of Ascentage Pharma Group International
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new stake in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned approximately 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access